This study is for people with Psoriatic Arthritis (PsA), a condition causing joint pain and swelling, and who are also overweight or have obesity. The study will test if taking two medicines, ixekizumab and tirzepatide, together helps reduce PsA symptoms and weight better than ixekizumab alone.

Participants will have up to 12 visits over 61 weeks, including screening and follow-ups. To join, participants must have had PsA for at least 6 months, have a body mass index (BMI) over 27, and at least one weight-related health condition like high blood pressure or type 2 diabetes.

People cannot join if they have type 1 diabetes, are on insulin for type 2 diabetes, have had obesity surgery, certain types of cancer, or other specific health issues. They also cannot have used ixekizumab or tirzepatide before.

• Length of study: Up to 61 weeks
• Number of visits: Up to 12
• Eligibility: Must have PsA and be overweight or obese